Provided by Tiger Fintech (Singapore) Pte. Ltd.

Tvardi Therapeutics Inc

28.50
+4.0016.33%
Volume:47.30K
Turnover:1.27M
Market Cap:266.79M
PE:-1.83
High:29.17
Open:24.50
Low:24.02
Close:24.50
Loading ...

Tvardi Therapeutics (TVRD) Receives a New Rating from BTIG

TIPRANKS
·
02 Jun

Tvardi Therapeutics files to sell 2.08M shares of common stock for holders

TIPRANKS
·
31 May

Tvardi Therapeutics (TVRD) Gets a Buy from BTIG

TIPRANKS
·
28 May

BRIEF-Tvardi Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of TTI-101 in Idiopathic Pulmonary Fibrosis

Reuters
·
27 May

Tvardi Therapeutics Inc - Topline Data From Revert Ipf Trial Expected in Q4 2025

THOMSON REUTERS
·
27 May

Tvardi Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of Tti-101 in Idiopathic Pulmonary Fibrosis

THOMSON REUTERS
·
27 May

Analysts Offer Insights on Healthcare Companies: Tvardi Therapeutics (TVRD) and ALX Oncology Holdings (ALXO)

TIPRANKS
·
24 May

Tvardi Therapeutics Initiated at Outperform by Oppenheimer

Dow Jones
·
21 May

Oppenheimer Initiates Tvardi Therapeutics at Outperform With $65 Price Target

MT Newswires Live
·
21 May

BUZZ-U.S. STOCKS ON THE MOVE-Xponential Fitness, Phillips 66, Amazon.com

Reuters
·
16 May

BUZZ-U.S. STOCKS ON THE MOVE-Deere, Lockheed Martin, Alibaba.com

Reuters
·
15 May

BTIG Initiates Tvardi Therapeutics at Buy With $55 Price Target

MT Newswires Live
·
15 May

BUZZ-BTIG starts Tvardi's coverage with 'buy' as co's drug to reverse lung scarring shows promise

Reuters
·
15 May

Tvardi Therapeutics Completes Merger with Cara Therapeutics, Secures Funding Through 2026

Reuters
·
14 May

BRIEF-Tvardi Therapeutics Announces First Quarter 2025 Results And Provides Business Update

Reuters
·
14 May

Tvardi Therapeutics Announces First Quarter 2025 Results and Provides Business Update

THOMSON REUTERS
·
14 May

Tvardi Therapeutics Inc - Completes Merger With Cara Therapeutics

THOMSON REUTERS
·
14 May

Tvardi Therapeutics: on Track for Multiple Phase 2 Data Readouts With Stat3 Inhibitor, Tti-101, With Lead Program in Ipf Expected in 2H 2025

THOMSON REUTERS
·
14 May

Tvardi Therapeutics: Cash, Cash Equivalents and Short-Term Investments at Closing Anticipated to Be Sufficient to Fund Operations Into 2H 2026

THOMSON REUTERS
·
14 May

Press Release: Tvardi Therapeutics Announces First Quarter 2025 Results and Provides Business Update

Dow Jones
·
14 May